[1] |
LIU Lijing, QIAN Hong, MENG Qingxin, ZHANG Xiang, HE Bin, HE Jianbin, WEI Yingmin.
Sinomenine inhibits oxidative stress and pulmonary fibrosis by activating the Keap1/Nrf2 signaling pathway
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 979-987.
|
[2] |
WANG Chaoyi, SONG Qiang, XIONG Xin, WANG Mengyuan.
Research progress on diagnosis and treatment of granulomatous lobular mastitis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 910-917.
|
[3] |
LI Yating, YUE Hongmei, LIU Miaomiao, XU Jinhui, WU Xingdong, ZHU Haobin.
The possibility of phosphodiesterase 4 inhibitors as drug therapy for idiopathic pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 818-823.
|
[4] |
FU Ting, LI Fang, PAN Dayan, XIA Yuanyuan, ZHANG Qiuyuan.
miR-718 from exosomes of lung cancer cells induces angiogenesis by targeting PTEN
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 624-632.
|
[5] |
LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin.
Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
|
[6] |
QIAO Hongliang, DING Ning, DENG Kaihong, LIU Binbin, DONG Chuanjiang, CHEN Xiaobo, ZOU Lili.
New progress in research on novel control strategies for methicillin-resistant staphylococcus aureus infection
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 676-687.
|
[7] |
ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun.
Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
|
[8] |
SHI Dawei, ZHENG Xiaoyong, JIN Xiaodan, ZHAO Xiaoman, CHEN Jie, DU Xingjun.
Implication of XPC rs2228001 polymorphism on the prognosis of patients with colorectal cancer who were treated with capecitabine-based adjuvant chemotherapy
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 391-399.
|
[9] |
ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin.
Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
|
[10] |
ZHANG Mingkang, MA Yanrong, JIN Yongwen, ZHOU Yan, CUI Ruirui, WU Xin'an.
Advances in clinical research on drug-induced acute interstitial nephritis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 419-428.
|
[11] |
NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang.
Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
|
[12] |
HE Yang, YANG Kui, LUAN Jiajie.
Effects of CDA-G208A gene polymorphism on the efficacy of gem-citabine in the first-line treatment of lung squamous cell carcinoma
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 299-306.
|
[13] |
LIU Nanyu, YUE Hongmei, SONG Peipei, WEI Jifang, WEI Yaqian, XIE Yingying, WANG Jiaqi .
PDE4 inhibitors serve as therapeutic targets for pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 355-360.
|
[14] |
WANG Jie, LI Long, CHEN Feng, LIU Shengfei.
Research progress of metformin in the pathogenesis of pulmonary fibrosis
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 235-240.
|
[15] |
LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang.
Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
|